In a premenopausal woman with low risk, early stage HR-positive breast cancer who is unable to discontinue a strong CYP2D6 inhibitor, do you use still utilize tamoxifen versus an AI with ovarian suppression?  


Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution